Search for Clinical Trial Results
Pancreatic Neuroendocrine Tumor - 45 Studies Found
Status | Study |
Completed |
Study Name: BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Condition: Pancreatic Neuroendocrine Tumors (pNET) Date: 2012-07-06 Interventions: Drug: BEZ235 (Stage 1) The investigational study drug used in this trial was BEZ235, which was supplied |
Active, not recruiting |
Study Name: RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors Condition: Pancreatic Neuroendocrine Tumor Date: 2007-12-17 Interventions:
|
Recruiting |
Study Name: Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria Condition: Pancreatic Neuroendocrine Tumors Date: 2016-07-20 |
Completed |
Study Name: Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Condition: Pancreatic Neuroendocrine Tumors Date: 2010-05-10 Interventions: Drug: Sunitinib Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg |
Recruiting |
Study Name: The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors Condition: Pancreatic Neuroendocrine Tumors Date: 2014-10-15 Interventions: Drug: sunitinib subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg on |
Not yet recruiting |
Study Name: Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Who Previously Failed to Sunitinib Condition: Pancreatic Neuroendocrine Tumour Metastatic Date: 2016-03-16 Interventions: Drug: Sunitinib Sunitinib 37.5 mg/day |
Completed |
Study Name: Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor Condition: Advanced Well-differentiated Pancreatic Neuroendocrine Tumor Date: 2013-04-29 Interventions: Drug: temozolomide or dacarbazine-based chemotherapy, endostatin |
Recruiting |
Study Name: 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors Condition: Gastro-entero-pancreatic Neuroendocrine Tumors Date: 2016-04-07 Interventions:
|
Not yet recruiting |
Study Name: Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment Condition: Pancreatic Neuroendocrine Tumors in MEN1 Date: 2016-03-02 Interventions: Drug: Somatostatin-Analog A long-acting somatostatin-analog will be applied. |
Terminated |
Study Name: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors Condition: Pancreatic Neuroendocrine Tumors (pNET) Date: 2012-06-25 Interventions:
|